Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis
Recruiting
N/A
Interventional Study
Female Infertility
NF-κB Ligand
RANKL
Osteoporosis
Follicle Development
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Peter Humaidan · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Female infertility presents a significant societal challenge that will be aggravated in the future due to delayed parenthood. Our translational research suggests that receptor activator of NF-κB ligand (RANKL) is a novel treatment target, during assisted reproductive techniques and that inhibition of this pathway may reduce the impact of aging on the ovary. RANKL is a regulator of bone health, and…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Female in the age of 18 or above, Normal AMH-value, able to give concent
Exclusion Criteria:
* Patients who have had autotransplanted ovarian tissue
Contacts
No contact information available.